

FDCA LICENCE NO. GTL/37/31

(FDCA, ISO 9001:2015, GLP, CPCSEA, NABL, ISO/IEC 17025, AYUSH, DSIR)

## RESEARCH REDEFINE

Form 30 (Pu	CERTIFICATE OF tle 150-E (f) – Report of test or		nstitution)
rorm 37 (Ku	FINISH PRO		institution)
Product Name	Hetgra ( Dolutegravir Tablets 50mg )		
Party Name and Address	Heet Healthcare. 507-508,5 <sup>th</sup> Floor,The Emporio by Kunj, Opposite 4D Square Mall,Near Vishwakarma Engineering Collage, Visat-Gandhinagar Highway Chandkheda,Ahmedabad,Gujarat India-382424		
Mfg By	N/A		
Manufacturer Licence No.	N/A	TR No.	N/A
		Testing Date	06/08/2019 to 07/08/2019
Batch No.	HDL-001	Document No.	ARL/3880/2019
Mfg. Date	12/2018	Qty. Received	30 Tablets
Exp. Date	11/2020	Test Qty.	10 Tablets
Date of Sample Receipt	31/07/2019	Test as Per	In House Method
Sample Id	ARL/HET/4240/2019	Release Date	07/08/2019

TESTS	STANDARDS & LIMITS	OBSERVATION
Assay of Dolutegravir	90.0 % to 110.0 %	96.61 %
* AND THE PROPERTY AND	Sponsor	ve is of standard quality and complies
Prepared By	A A	pproved By/Authorized By
pleeli	AHMEDABAD SP	1907/08/2019
Ms. Anita Patel	105 V 4.05	Dr. Rina H. Gokani
	Assay of Dolutegravir on: In the opinion of the under rescribed standards given by S  Prepared By	Assay of Dolutegravir  90.0 % to 110.0 %  on: In the opinion of the undersigned, the sample referred to aborescribed standards given by Sponsor.  Prepared By  AHMEDABAD  AI  AHMEDABAD  AI  AI  AI  AI  AI  AI  AI  AI  AI

## Note:

- The results listed refer only to the samples and applicable parameters, endorsement of product is neither inferred nor implied.
- Total liability of our laboratory is limited to the supplied test samples by the customer pertaining to above specified batch only and up to the invoiced amount only.
- 3. Sample drawn and submitted by the sponsor for Analysis unless otherwise stated.
- 4. The analysis has been performed with test method suggested / provided from the client side with / without method validation / verification performed at Accuprec site.

ARL/FORMAT/0017-04 PAGE 1 OF 1



RESEARCH **REDEFINE** 

FDCA LICENCE NO. GTL/37/31

(FDCA, ISO 9001:2015, GLP, CPCSEA, NABL, ISO/IEC 17025, AYUSH, DSIR)

Form 39 (Ru	CERTIFICATE OF tle 150-E (f) – Report of test or FINISH PRO	analysis by approved i	nstitution)
Product Name	Tenhet (Tenofovir Alafenamide 25mg Tablet)		
Party Name and Address	Heet Healthcare. 507-508,5 <sup>th</sup> Floor,The Emporio by Kunj, Opposite 4D Square Mall,Near Vishwakarma Engineering Collage, Visat-Gandhinagar Highway Chandkheda,Ahmedabad,Gujarat India-382424		
Mfg By	N/A		
Manufacturer Licence No.	N/A	TR No.	N/A
		Testing Date	06/08/2019 to 07/08/2019
Batch No.	TNC-001	Document No.	ARL/3881/2019
Mfg. Date	03/2019	Qty. Received	30 Tablets
Exp. Date	09/2020	Test Qty.	10 Tablets
Date of Sample Receipt	31/07/2019	Test as Per	In House Method
Sample Id	ARL/HET/4239/2019	Release Date	07/08/2019

SR. NO.	TESTS	STANDARDS & LIMITS	OBSERVATION
1.	Assay of Tenofovir	90.0 % to 110.0 %	94.52 %
	on: In the opinion of the und rescribed standards given by Prepared By	Sponsor.	pproved By/Authorized By
	bleefit		1 Porto 8/2019
Ms. Anita Patel		(3)	Dr. Rina H. Gokani
		END OF REPORT	

## Note:

- 1. The results listed refer only to the samples and applicable parameters, endorsement of product is neither inferred nor implied.
- 2. Total liability of our laboratory is limited to the supplied test samples by the customer pertaining to above specified batch only and up to the invoiced amount only.
- 3. Sample drawn and submitted by the sponsor for Analysis unless otherwise stated.
- 4. The analysis has been performed with test method suggested / provided from the client side with / without method validation / verification performed at Accuprec site.

ARL/FORMAT/0017-04

PAGE 1 OF 1